Inthera Bioscience Overview

  • Founded
  • 2013
Founded
  • Status
  • Private
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $11.2M
Latest Deal Amount
  • Investors
  • 4

Inthera Bioscience General Information

Description

Developer of first-in-class targeted small molecule therapies designed to provide treatment for solid tumors. The company's therapies are focused on the development of novel first-in-class oral agents blocking aberrant cell signaling in solid tumors and uses proprietary technology platform to rationally design protein-protein interaction inhibitors, enabling patient to begin treatment more quickly and result in a higher likelihood of a successful treatment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Drug Discovery
Primary Office
  • Einsiedlerstrasse 34
  • 8820 Waedenswil
  • Switzerland
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Inthera Bioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A) 26-Jun-2018 $11.2M 000.00 000.00 Completed Pre-Clinical Trials
2. Seed Round 14-Dec-2015 00.000 00.000 Completed Product Development
1. Seed Round 30-Apr-2014 $226K $226K 00.000 Completed Generating Revenue
To view Inthera Bioscience’s complete valuation and funding history, request access »

Inthera Bioscience Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 000,000 000.00 000.00 00 000.00 00.000
Seed 00,000 000.00 000.00 00 000.00 0.000
Seed 277,776 $7.98 $7.98 1x $7.98 20.84%
Ordinary 25,000 $9.34 $9.34 1x $9.34 1.88%
To view Inthera Bioscience’s complete cap table history, request access »

Inthera Bioscience Executive Team (7)

Name Title Board Seat Contact Info
Ulrich Kessler Co-Founder & Chief Executive Officer
Roland Walder Board Member & Chief Financial Officer
Bernd Hentsch Ph.D Chief Development Officer
Ralph Lindemann Ph.D Chief Scientific Officer
Pavel Pisa Ph.D Co-Founder & Owner
You’re viewing 5 of 7 executive team members. Get the full list »

Inthera Bioscience Board Members (8)

Name Representing Role Since
Anker Lundemose Ph.D Self Board Member 000 0000
Emmanuelle Coutanceau Ph.D Novo Holdings Board Member 000 0000
Jasper Bos Ph.D M Ventures Board Member 000 0000
Keno Gutierrez Ph.D M Ventures Board Member 000 0000
Klaus Schollmeier Ph.D Self Chairman 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Inthera Bioscience Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Aglaia Management B.V. Venture Capital Minority 000 0000 000000 0
Eva Capital Accelerator/Incubator Minority 000 0000 000000 0
M Ventures Corporate Venture Capital Minority 000 0000 000000 0
Novo Holdings Venture Capital Minority 000 0000 000000 0
To view Inthera Bioscience’s complete investors history, request access »